ImmuPharma plc (AIM:IMM)
London
· Delayed Price · Currency is GBP · Price in GBX 1.618
+0.098 (6.41%)
Aug 15, 2025, 4:35 PM GMT+1
ImmuPharma Income Statement
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | - | - | - | - | 0.12 | 0.13 | Upgrade
|
| Revenue Growth (YoY) | - | - | - | - | -6.57% | 62.55% | Upgrade
|
| Gross Profit | - | - | - | - | 0.12 | 0.13 | Upgrade
|
| Selling, General & Admin | 1.26 | 1.03 | 1.02 | 0.85 | 1.01 | 1.76 | Upgrade
|
| Research & Development | 1.38 | 1.16 | 2.02 | 2.02 | 3.65 | 2.37 | Upgrade
|
| Other Operating Expenses | 0.39 | 0.39 | -0.12 | - | - | - | Upgrade
|
| Operating Expenses | 3.14 | 2.68 | 3.06 | 3.03 | 5.28 | 5.72 | Upgrade
|
| Operating Income | -3.14 | -2.68 | -3.06 | -3.03 | -5.16 | -5.59 | Upgrade
|
| Interest Expense | -0.88 | -0 | -0 | -0 | -0.12 | -0.23 | Upgrade
|
| Interest & Investment Income | - | 0.01 | 0 | 0 | 0 | 0.04 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.15 | -0.15 | -0 | -0.02 | 0 | -0.15 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.04 | 0.04 | -0.35 | -1.41 | -2.23 | -1.32 | Upgrade
|
| EBT Excluding Unusual Items | -4.13 | -2.78 | -3.42 | -4.46 | -7.51 | -7.25 | Upgrade
|
| Other Unusual Items | - | - | - | - | -1.43 | - | Upgrade
|
| Pretax Income | -4.13 | -2.78 | -3.42 | -4.46 | -8.94 | -7.25 | Upgrade
|
| Income Tax Expense | -0.2 | -0.3 | -0.5 | -0.65 | -0.77 | -0.39 | Upgrade
|
| Net Income | -3.93 | -2.48 | -2.92 | -3.81 | -8.17 | -6.86 | Upgrade
|
| Net Income to Common | -3.93 | -2.48 | -2.92 | -3.81 | -8.17 | -6.86 | Upgrade
|
| Shares Outstanding (Basic) | 448 | 416 | 362 | 303 | 251 | 200 | Upgrade
|
| Shares Outstanding (Diluted) | 448 | 416 | 362 | 303 | 251 | 200 | Upgrade
|
| Shares Change (YoY) | 11.05% | 15.04% | 19.51% | 20.60% | 25.47% | 30.45% | Upgrade
|
| EPS (Basic) | -0.01 | -0.01 | -0.01 | -0.01 | -0.03 | -0.03 | Upgrade
|
| EPS (Diluted) | -0.01 | -0.01 | -0.01 | -0.01 | -0.03 | -0.03 | Upgrade
|
| Free Cash Flow | -1.9 | -1.77 | -1.36 | -2.45 | -4.88 | -3.69 | Upgrade
|
| Free Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.01 | -0.02 | -0.02 | Upgrade
|
| Gross Margin | - | - | - | - | 100.00% | 100.00% | Upgrade
|
| Operating Margin | - | - | - | - | -4359.84% | -4412.70% | Upgrade
|
| Profit Margin | - | - | - | - | -6906.55% | -5415.72% | Upgrade
|
| Free Cash Flow Margin | - | - | - | - | -4126.83% | -2912.91% | Upgrade
|
| EBITDA | -3.14 | -2.61 | -3.03 | -2.91 | -5.05 | -5.42 | Upgrade
|
| D&A For EBITDA | 0.01 | 0.06 | 0.04 | 0.12 | 0.11 | 0.17 | Upgrade
|
| EBIT | -3.14 | -2.68 | -3.06 | -3.03 | -5.16 | -5.59 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.